Voyager Therapeutics, Inc. (VYGR) stock
Close on Nov 11, 2026Market cap $108.45MP/E –Yield –
Voyager Therapeutics, Inc. saw revenue fall 19.8% to $25.11M over the twelve months to Sep 30, 2026. Free cash flow was -$109.83M. At the latest close the market valued the company at $108.45M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $108.45M
- P/E ratio
- –
- Price to sales
- 4.32
- Price to book
- 0.80
- Dividend yield
- –
- Free cash flow yield
- -101.28%
Fundamentals
- Revenue
- $25.11M
- Net income
- -$104.53M
- EPS, diluted
- -$1.74
- Free cash flow
- -$109.83M
- Book value per share
- $2.19
- Diluted shares
- 62M
Trading
- Next earnings
- Q3 FY2026, expected soon
- Previous close
- $1.82
- Open
- $1.84
- Day's range
- $1.75 – $1.84
- Volume
- 624,164
- Average volume (20 days)
- 1,038,956
- Index membership
- Russell 2000 (since Jun 2023), Russell 3000 (since Nov 2025)
- Beta (5 years)
- 1.21
- 52-week range
- $1.68 – $5.48
- RSI (14 days)
- 39.0
- Volatility (1 year)
- 61.4%
- Relative volume
- 0.88×
- WACC
- 10.9%
On 1 of our idea list: More cash than they're worth
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2015, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | VYGR | S&P 500 | Difference | VYGR per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -28.2% | -2.4% | −25.8 pts | ||
| 3 months | -45.0% | -1.2% | −43.8 pts | ||
| Year to date | -55.2% | +12.3% | −67.5 pts | ||
| 1 year | -58.7% | +12.4% | −71.1 pts | ||
| 3 years | -72.3% | +78.8% | −151.1 pts | -34.8% | +21.4% |
| 5 years | -49.6% | +75.2% | −124.7 pts | -12.8% | +11.9% |
| 10 years | -85.6% | +311.1% | −396.7 pts | -17.6% | +15.2% |
Thirteen years at a glance
Fiscal years 2013 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Voyager Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Update
- Update
- Results
About Voyager Therapeutics
Biological Products, (No Diagnostic Substances)
Voyager Therapeutics is a biotechnology company focused on developing therapies for severe neurological conditions, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and Friedreich's ataxia. The company develops intravenous gene therapies and antibody treatments utilizing its proprietary TRACER adeno-associated virus capsid discovery platform and NeuroShuttle delivery system, which facilitate transport across the blood-brain barrier. Its pipeline consists of wholly owned drug candidates, such as tau-directed programs for Alzheimer's disease, as well as partnered programs. Its customers and commercial partners include global pharmaceutical and biotechnology corporations such as Novartis, Neurocrine Biosciences, and Alexion, which license Voyager's capsids and collaborate on research, development, and potential commercialization.
Company profile, executives and historyVoyager Therapeutics stock: common questions
What is Voyager Therapeutics's stock price?
VYGR closed at $1.76 on Nov 11, 2026, down 3.56% on the day. Over the past 52 weeks it traded between $1.68 and $5.48.
What is Voyager Therapeutics's market cap?
Voyager Therapeutics was worth $108.45M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is VYGR's P/E ratio?
Voyager Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.74), so it has no meaningful P/E ratio.
How much revenue does Voyager Therapeutics make?
Voyager Therapeutics reported revenue of $25.11M for the twelve months to Sep 30, 2026, down 19.8% from a year earlier.
Does Voyager Therapeutics pay a dividend?
No. Voyager Therapeutics has not paid a cash dividend over the last twelve months.
When does Voyager Therapeutics report earnings next?
Voyager Therapeutics's Q3 FY2026 results are due soon; the company has not yet filed them with the SEC.
How has VYGR stock performed over the past year?
Including dividends, VYGR returned -58.7% over the past year, against +12.4% for the S&P 500.
How many VYGR shares are sold short?
4M shares were sold short at the latest FINRA report, 7.29% of the float, or 4.1 days of average trading volume.
Who are Voyager Therapeutics's competitors?
Companies most similar to Voyager Therapeutics by business, industry and size include SGMOQ, CCCC, QURE, ALEC, PRTA.
See a number that looks wrong?